JP2005502672A5 - - Google Patents

Download PDF

Info

Publication number
JP2005502672A5
JP2005502672A5 JP2003524529A JP2003524529A JP2005502672A5 JP 2005502672 A5 JP2005502672 A5 JP 2005502672A5 JP 2003524529 A JP2003524529 A JP 2003524529A JP 2003524529 A JP2003524529 A JP 2003524529A JP 2005502672 A5 JP2005502672 A5 JP 2005502672A5
Authority
JP
Japan
Prior art keywords
composition
polypeptide
angiogenic
composition according
coronary artery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003524529A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502672A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/027520 external-priority patent/WO2003020215A2/en
Publication of JP2005502672A publication Critical patent/JP2005502672A/ja
Publication of JP2005502672A5 publication Critical patent/JP2005502672A5/ja
Pending legal-status Critical Current

Links

JP2003524529A 2001-08-29 2002-08-29 サイモシンβ4、類似体、アイソフォームおよびその他の誘導体を用いて心筋障害の発生前、発生中または発生後に発生する炎症、損傷およびその他の変化を治癒または予防する方法 Pending JP2005502672A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31534701P 2001-08-29 2001-08-29
PCT/US2002/027520 WO2003020215A2 (en) 2001-08-29 2002-08-29 Methods of treating mycocardial event related coditions with thymosin beta 4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009123032A Division JP2009221211A (ja) 2001-08-29 2009-05-21 サイモシンβ4、類似体、アイソフォームおよびその他の誘導体の使用

Publications (2)

Publication Number Publication Date
JP2005502672A JP2005502672A (ja) 2005-01-27
JP2005502672A5 true JP2005502672A5 (enExample) 2006-01-05

Family

ID=23223988

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003524529A Pending JP2005502672A (ja) 2001-08-29 2002-08-29 サイモシンβ4、類似体、アイソフォームおよびその他の誘導体を用いて心筋障害の発生前、発生中または発生後に発生する炎症、損傷およびその他の変化を治癒または予防する方法
JP2009123032A Ceased JP2009221211A (ja) 2001-08-29 2009-05-21 サイモシンβ4、類似体、アイソフォームおよびその他の誘導体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009123032A Ceased JP2009221211A (ja) 2001-08-29 2009-05-21 サイモシンβ4、類似体、アイソフォームおよびその他の誘導体の使用

Country Status (8)

Country Link
US (1) US9056087B2 (enExample)
EP (1) EP1427432A4 (enExample)
JP (2) JP2005502672A (enExample)
CN (2) CN101549148A (enExample)
AU (1) AU2002336408B2 (enExample)
CA (1) CA2458883C (enExample)
MX (1) MXPA04001942A (enExample)
WO (1) WO2003020215A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2266595A3 (en) * 2002-02-06 2011-07-06 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
WO2006076254A2 (en) * 2005-01-11 2006-07-20 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing respiratory microbial infection of respiratory tissue
US20080051348A1 (en) * 2002-02-06 2008-02-28 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
CN1852727A (zh) * 2003-03-31 2006-10-25 雷金纳克斯生物制药公司 递送胸腺素β4、类似物、同工型和其它衍生物的组合物和方法
CA2532542A1 (en) * 2003-07-18 2005-01-27 Regenerx Biopharmaceuticals, Inc. Treatment or prevention of damage due to radiation exposure
US20090053194A1 (en) * 2003-12-22 2009-02-26 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
WO2005087805A1 (en) * 2004-03-05 2005-09-22 Regenerx Biopharmaceuticals, Inc. Treating or preventing extracellular matrix build-up
JP2008510732A (ja) * 2004-08-20 2008-04-10 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 心臓組織の損傷を処置、予防、阻害、または緩和する方法
US7531318B2 (en) 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
CA2612522A1 (en) * 2005-06-17 2006-12-28 Regenerx Biopharmaceuticals, Inc. Lkktet and/or lkktnt peptide compositions and methods
JP2009502938A (ja) * 2005-07-26 2009-01-29 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 鬱血性心不全が原因である組織の劣化、損傷、または破損を処置または予防する方法
WO2007014254A2 (en) * 2005-07-26 2007-02-01 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to hypertrophic muscle disease
CN100372572C (zh) * 2005-09-29 2008-03-05 北京诺思兰德生物技术有限责任公司 携带人胸腺素β4基因的重组质粒
US8399412B2 (en) * 2006-10-06 2013-03-19 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions
HUP0600814A3 (en) * 2006-10-27 2009-08-28 Biostatin Gyogyszerkutato Fejl Peptides for activation of angiogenesis, pharmaceutical compounds containing same and use of these compounds
MX2010010177A (es) * 2008-03-17 2012-08-23 Regenerx Biopharmaceuticals Fragmentos de beta timosina mejorada.
KR101297037B1 (ko) * 2010-03-26 2013-08-14 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
BR112013000923A2 (pt) * 2010-07-14 2016-05-17 Adistem Ltd método de tratamento de hiv ou aids
WO2012044783A2 (en) * 2010-09-30 2012-04-05 Regenerx Biopharmaceuticals, Inc. Method of achieving a thymosin beta 4 concentration in a human patient
JP6889771B2 (ja) * 2016-07-18 2021-06-18 リジェンツリー リミテッド ライアビリティ カンパニー ドライアイ症候群を治療する方法
WO2021225960A2 (en) * 2020-05-05 2021-11-11 Regenerx Biopharmaceuticals, Inc. Beta thymosin peptides for treating viral infections
CN111821424B (zh) * 2020-07-21 2023-03-31 广东海洋大学深圳研究院 胸腺素及其衍生物的应用和治疗抑郁症的药物
CN112023027B (zh) * 2020-07-21 2023-03-14 广东海洋大学 胸腺素或其衍生物的应用和治疗快感缺乏型抑郁症的药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
JPS61500431A (ja) 1982-12-09 1986-03-13 ビルトン,ジエラルド エル. 傷治癒に有用な活性化され、安定化された酵素
US4543340A (en) 1983-04-07 1985-09-24 George Washington University Radioimmunoassay of thymosin β4
JPH02124815A (ja) 1987-10-29 1990-05-14 Takeda Chem Ind Ltd 血管形成促進剤
US5654267A (en) 1988-12-20 1997-08-05 La Jolla Cancer Research Center Cooperative combinations of ligands contained within a matrix
JPH03178988A (ja) 1989-09-14 1991-08-02 Takeda Chem Ind Ltd 生理活性物質tan―883、その製造法および用途
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
EP0725652A1 (en) 1993-10-07 1996-08-14 The George Washington University Medical Center METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN $g(b) 4?
US5578570A (en) 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
AU3733295A (en) 1994-10-06 1996-05-02 Alpha 1 Biomedicals, Inc. Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i
US5663071A (en) 1996-06-17 1997-09-02 Children's Medical Center Corporation Human thymosin β 15 gene, protein and uses thereof
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
GB9806632D0 (en) 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
JP4301602B2 (ja) 1998-09-28 2009-07-22 株式会社マルハニチロ水産 血管内皮細胞増殖促進剤
PT1100529E (pt) 1998-07-30 2005-10-31 Us Gov Health & Human Serv A timosina beta 4 promove a preparacao de feridas
US7560280B2 (en) * 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)

Similar Documents

Publication Publication Date Title
JP2005502672A5 (enExample)
CA2458883C (en) Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
RU2000109305A (ru) ЗАЖИВЛЕНИЕ ПЕРЕЛОМОВ С ПОМОЩЬЮ АНАЛОГОВ ПЕПТИДА, ПОДОБНОГО ПАРАТИРЕОИДНОМУ ГОРМОНУ (РТНrР)
DE69930872D1 (de) Antikörper gegen verkürzten vegf-d und deren verwendungen
JP2002509854A5 (enExample)
NO941186D0 (no) Hormonanaloger med multiple CTP-forlengelser
CA2223611A1 (en) Appetite regulating compositions
CA2727085A1 (en) Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
ATE522563T1 (de) Verzweigte polyalkylenglykole
AU2002336408A1 (en) Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
JP2005506293A5 (enExample)
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
CA2473996A1 (en) Methods and compositions for the promotion of hair growth utilizing actin binding peptides
US20060246057A1 (en) Treatment or prevention of damage due to radiation exposure
JP2004525988A5 (enExample)
ES2338633T3 (es) Inhibicion o inversion del envejecimiento de la piel por medio de peptidos secuestradores de actina.
JP2004527463A5 (enExample)
AU2004308378A1 (en) Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
US20040067227A1 (en) Inhibition or reversal of skin aging by actin-sequestering peptides
US20240116990A1 (en) Compositions and Methods of Treatment Using CRRL 191
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
Rohde et al. Structure of antigenic determinants in the N-terminal region of dermatosparactic sheep procollagen type I
CA2558039A1 (en) Treating or preventing extracellular matrix build-up
ATE415415T1 (de) Bicyclische oligopeptide und deren verwendung als glucagon rezeptorantagonist